Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 19/20 | 0.92 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325145 | 0.92 | MTNR1B (1.00) | MTNR1BMTNR1ATSHRMAPK1 | |
| SCHEMBL6320905 | 0.88 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| SCHEMBL6324146 | 0.87 | MTNR1B (1.00) | MTNR1BMTNR1ACYP3A4CYP2C19 | |
| SCHEMBL6319610 | 0.87 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| SCHEMBL6318173 | 0.86 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| SCHEMBL6321674 | 0.85 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| SCHEMBL6318855 | 0.85 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| SCHEMBL6319940 | 0.84 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| SCHEMBL6321313 | 0.83 | MTNR1B (0.88) | MTNR1BMTNR1A | |
| SCHEMBL6321566 | 0.80 | MTNR1B (1.00) | MTNR1BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908931-B2 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | claimed |
| US-20040235891-A1 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | claimed |
| US-6908931-B2 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040235891-A1 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235891-A1 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | MTNR1A, MTNR1B, PER2 | MTNR1B 2/4885MTNR1A 1/4885ALDH1A1 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.